Clinical Trial Update: Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of toripalimab and surufatinib with concurrent chemoradiotherapy for limited-stage small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer

Drugs mentioned

• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Toripalimab, Surufatinib | Phase 2 | Status: RECRUITING